• Combination drugs Levoximed and secnidоx in the treatment of pelvic inflammatory diseases (PID)

Combination drugs Levoximed and secnidоx in the treatment of pelvic inflammatory diseases (PID)

HEALTH OF WOMAN. 2016.7(113):115–120 
 

Combination drugs Levoximed and secnidоx in the treatment of pelvic inflammatory diseases (PID)


Nosenko O. M.

Odessa national medical University


The objective: was to investigate the clinical efficacy and tolerability of oral administration of a combination of drugs: Levoximed and Secnidox in patients with uncomplicated forms of PID.


Patients and methods. The study included 30 patients of reproductive age with uncomplicated forms of PID and 30 gynecological conditionally healthy women. Therapy PID by Levoximed held for 14 days at 500 mg per day in combination with Secnidox – 2 tablets (2.0 g) once in one step. Assessed clinical variables, eradication of pathogens, tolerability and safety.


Results. The treatment resulted in the elimination of pain in 96.67% of patients; dizuria events – at 46.67%; abnormal discharge from the genital tract – at 86.67%; low grade temperature – at 36.67%. After treatment there was a complete eradication of obligate pathogens and elimination of opportunistic pathogens in diagnostically significant quantities. Tolerability of the combination of drugs Levoximed and Secnidox recognized as excellent in 76.67% of patients, good – at 16.67%, satisfactory – at 6.67%.


Conclusions. High clinical efficiency, extended range of antimicrobial activity synergistic products, excellent tolerability and safety allow us to recommend a combination of Levoximed and Secnidox for empirical treatment of uncomplicated forms of PID in an outpatient setting.


Key words: inflammatory diseases of the pelvic organs, Levoximed, Secnidox, clinical efficacy, eradication of the infectious agent, tolerability, safety.


REFERENCES

1. Avramenko NV. 2014. Inflammatory diseases of the pelvic organs in women as the leading factor in the formation of tube-peritoneal sterility. Zaporozhye Medical Journal 4(85):63-68.

2. Batyrshina SV. 2010. Urogenital chlamydiosis: antibiotic therapy and methods for potentiating its effectiveness. Practical medicine 4(430):57-62.

3. Vdovichenko YP, Gopchuk EI. 2012. Inflammatory diseases of the pelvic organs – a comprehensive approach for effective therapy. Women's Health 4:102-108.

4. Dubchak AE, Milevsky AV, Dougan EN. 2013. Non-specific inflammatory diseases of the pelvic organs in women. Women's Health 2:51-55.

5. Kosei NV. 2013. Modern principles of treatment of pelvic inflammatory disease. Reproductive Endocrinology 1:78-85. http://dx.doi.org/10.18370/2309-4117.2013.9.78-85

6. Rafalskiy VV, Dougan EV, Ivanyan AN et al. 2011. The practice of using antimicrobial agents in women with inflammatory diseases of the pelvic organs in the Russian Federation. Obstetrics and Gynecology 5:88-93.

7. Practical Guide to anti-infective chemotherapy. Under. Ed. LS Stratchounski, YB Belousov, SN Kozlov. 2007. Access: http://www.antibiotic.ru/ab/038-42.shtml. Title screen.

8. Harrison JJ, Turner RJ, Marques LLR et al. 2005. Biofilms: A new understanding of these microbial communities is driving a revolution that may transform the science of microbiology. Am. Sci. 93:508–515. http://dx.doi.org/10.1511/2005.56.977

9. Lu ZK, Yuan J, Li M et al. 2015. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin. Drug Saf. 14(2):295-303. http://dx.doi.org/10.1517/14740338.2015.989210.

10. Melkumyan AR, Priputnevich TV, Ankirskaya AS et al. 2015. Effects of antibiotic treatment on the lactobacillus composition of vaginal microbiota. Bull. Exp. Biol. Med. 158(6):766-768. http://dx.doi.org/10.1007/s10517-015-2857-1.

11. Judlin P, Thiebaugeorges O. 2009. Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. Eur. J. Obstet. Gynecol. Reprod. Biol. 145(2):177-179. http://dx.doi.org/10.1016/j.ejogrb.2009.04.025.

12. Sexually Transmitted Diseases: Summary of 2015 CDC Treatment Guidelines. J. Miss. State. Med. Assoc. 56(12):372-375.

13. Soyama Y, Mizuhara H, Iwata Y. 1992. Fundamental study on levofloxacin in the field of obstetrics and gynecology. Jpn. J. Antibiot. 45(3):265-269. PMid:1512923

14. Gildert DN, Moellering RC, Sande MA et al. 2015. The Sanford Guide to Antimicrobial Therapy. 45th Edition. USA: Antimicrobial Therapy Inc. ISBN-13:978-1930808843.